Blastic plasmacytoid dendritic cell neoplasia

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
BCL-2 inhibitor 1 substance
Phase II: 1 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • French Innovative Leukemia Organization Academic
    TAGRAXOFUSP; VENETOCLAX
    2024-511003-42-00 1 country 2025 n=33
    Recruiting

Phase I (Other)

1 trial
  • Celgene Corp. Commercial
    IMP not specified
    2023-503427-26-00 2 countries 2023 n=14
    Ended

Phase I (First in Human)

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    SAR-443579
    2023-508357-58-00 2 countries 2022 n=57
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Celgene Corp. Commercial 1 Phase I (Other) 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase I (First in Human) 0
French Innovative Leukemia Organization Academic 1 Phase II 1
New trials by year
2022
1
2023
1
2025
1
← All indication landscapes